A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing

Genetics in Medicine

Volumn 18, Issue 5, 2016, Pages 467-475

  Berg, Jonathan S ^a   Foreman, Ann Katherine M ^a   O'Daniel, Julianne M ^a   Booker, Jessica K ^a   Boshe, Lacey ^a   Carey, Timothy ^a   Crooks, Kristy R ^a   Jensen, Brian C ^a   Juengst, Eric T ^a,b   Lee, Kristy ^a   Nelson, Daniel K ^a   Powell, Bradford C ^a   Powell, Cynthia M ^a   Roche, Myra I ^a   Skrzynia, Cecile ^a   Strande, Natasha T ^a   Weck, Karen E ^a   Wilhelmsen, Kirk C ^a   Evans, James P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE SEQUENCE; GENERAL PRACTITIONER; HUMAN; INCIDENTAL FINDING; KNOWLEDGE BASE; RANDOM SAMPLE; SOMATIC MUTATION; CHROMOSOMAL MAPPING; GENETIC DISEASES, INBORN; GENETIC SCREENING; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; PATHOLOGY; PROCEDURES;

CHROMOSOME MAPPING; GENETIC DISEASES, INBORN; GENETIC TESTING; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INCIDENTAL FINDINGS;

EID: 84964898627     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.104     Document Type: Article

References (40)

1. Presidential Commission for the Study of Bioethical Issues. Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts. 2013. http://bioethics. gov/sites/default/files/FINALAnticipateCommunicate-PCSBI-0.pdf. Accessed 2 December 2014.
2. Berg JS, Khoury MJ, Evans J P. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 2011;13:499-504.
3. Berg JS, Adams M, Nassar N, et al. An informatics approach to analyzing the incidentalome. Genet Med 2013;15:36-44.
4. Berg JS, Amendola LM, Eng C, et al.; Members of the CSER Actionability and Return of Results Working Group. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med 2013;15:860-867.
5. Green RC, Berg JS, Grody WW, et al.; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-574.
6. Holm IA, Taylor PL. The Informed Cohort Oversight Board: From Values to Architecture. Minn J Law Sci Technol 2012;13:669-690.
7. van El CG, Cornel MC, Borry P, et al.; ESHG Public and Professional Policy Committee. Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2013;21:580-584.
8. Lindor NM, Johnson KJ, McCormick JB, Klee EW, Ferber MJ, Farrugia G. Preserving personal autonomy in a genomic testing era. Genet Med 2013;15:408-409.
9. Berg JS. Response to Lindor et al. Genet Med 2013;15:409-410.
10. Goddard KA, Whitlock E P, Berg JS, et al. Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genet Med 2013;15:721-728.
11. Burke W, Antommaria AH, Bennett R, et al. Recommendations for returning genomic incidental findings? We need to talk! Genet Med 2013;15:854-859.
12. Ross L F, Rothstein MA, Clayton EW. Premature guidance about whole-genome sequencing. Per Med 2013;10.
13. Wolf SM, Annas GJ, Elias S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. Science 2013;340:1049-1050.
14. Pagon RA, Adam M P, Ardinger HH et al., eds. GeneReviews. University of Washington: Seattle, WA, 1993-2014.
15. Dorschner MO, Amendola LM, Turner EH, et al.; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Actionable, pathogenic incidental findings in 1, 000 participants' exomes. Am J Hum Genet 2013;93:631-640.
16. Johnston JJ, Rubinstein WS, Facio FM, et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012;91:97-108.
17. Lawrence L, Sincan M, Markello T, et al. The implications of familial incidental findings from exome sequencing: the NIH Undiagnosed Diseases Program experience. Genet Med 2014;16:741-750.
18. Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 2010;33:501-506.
19. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
20. Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet 2007;15:724-733.
21. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
22. National Hemophilia Foundation. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). http://www.hemophilia.org/sites/default/files/document/files/masac179.pdf. Accessed 2 December 2014.
23. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-343.
24. Eng C. PTEN hamartoma tumor syndrome (PHTS). In: GeneReviews® [Internet], Pagon RA, Adam M P, Ardinger HH et al., eds. University of Washington: Seattle, WA, 2014.
25. Pflaumer A, Davis AM. Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ 2012;21:96-100.
26. Khoury A, Marai I, Suleiman M, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2013;10:1671-1675.
27. Cirino AL, Ho C. Hypertrophic cardiomyopathy overview. In: GeneReviews, Pagon RA, Adam M P, Ardinger HH et al., eds. University of Washington: Seattle, WA, 2014.
28. Gersh BJ, Maron BJ, Bonow RO, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761-2796.
29. Klepper J, Diefenbach S, Kohlschütter A, Voit T. Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. Prostaglandins Leukot Essent Fatty Acids 2004;70:321-327.
30. Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010;133(Pt 3):655-670.
31. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002;99:1938-1942.
32. Varga E. Inherited thrombophilia: key points for genetic counseling. J Genet Couns 2007;16:261-277.
33. Andersen K F, Altaf R, Krarup-Hansen A, et al. Malignant pheochromocytomas and paragangliomas -The importance of a multidisciplinary approach. Cancer Treat Rev 2011;37:111-119.
34. Young AL, Baysal BE, Deb A, Young WF Jr. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 2002;87: 4101-4105.
35. Heufelder AE, Klee GG, Wynne AG, Gharib H. Familial dysalbuminemic hyperthyroxinemia: cumulative experience in 29 consecutive patients. Endocr Pract 1995;1:4-8.
36. Pavlovich C P, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005;173:1482-1486.
37. Pomianowski P, Elefteriades JA. The genetics and genomics of thoracic aortic disease. Ann Cardiothorac Surg 2013;2:271-279.
38. Ajjan RA, Owen KR. Glucokinase MODY and implications for treatment goals of common forms of diabetes. Curr Diab Rep 2014;14:559.
39. Valstar MJ, Ruijter GJ, van Diggelen O P, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008;31:240-252.
40. Gimm O, Greco A, Hoang-Vu C, Dralle H, Pierotti MA, Eng C. Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:2784-2787.